Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax: 2022-2025

Historic Long-Term Deferred Tax for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Sep 2025 value amounting to $201.3 million.

  • Kiniksa Pharmaceuticals International's Long-Term Deferred Tax fell 3.22% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.3 million, marking a year-over-year decrease of 3.22%. This contributed to the annual value of $211.2 million for FY2024, which is 3.71% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Long-Term Deferred Tax is $201.3 million, which was down 2.06% from $205.5 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Long-Term Deferred Tax peaked at $219.3 million during Q4 2023, and registered a low of $184.4 million during Q1 2023.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Long-Term Deferred Tax had a median value of $205.5 million in 2025 and averaged $205.0 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first climbed by 18.22% in 2023, then fell by 3.71% in 2024.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Long-Term Deferred Tax (Quarterly) stood at $185.5 million in 2022, then increased by 18.22% to $219.3 million in 2023, then dropped by 3.71% to $211.2 million in 2024, then fell by 3.22% to $201.3 million in 2025.
  • Its last three reported values are $201.3 million in Q3 2025, $205.5 million for Q2 2025, and $208.2 million during Q1 2025.